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Pdditive Beneficial Effects of
enofibrate Combined With Atorvastatin
n the Treatment of Combined Hyperlipidemia
wang Kon Koh, MD, FACC,* Michael J. Quon, MD, PHD,‡ Seung Hwan Han, MD,*
ook-Jin Chung, MD,* Jeong Yeal Ahn, MD,† Yiel-Hea Seo, MD,† In Suck Choi, MD,*
ak Kyun Shin, MD*
ncheon, Korea; and Bethesda, Maryland
OBJECTIVES We compared vascular and metabolic responses (and adverse responses) to statin and fibrate
therapies alone or in combination in patients with combined hyperlipidemia.
BACKGROUND The mechanisms of action for statins and fibrates are distinct.
METHODS Fifty-six patients were given atorvastatin 10 mg and placebo, atorvastatin 10 mg and
fenofibrate 200 mg, or fenofibrate 200 mg and placebo daily during each two-month
treatment period of a randomized, double-blind, placebo-controlled crossover trial with two
washout periods of two months’ each.
RESULTS Lipoproteins were changed to a greater extent with combined therapy when compared with
atorvastatin or fenofibrate alone. Flow-mediated dilator response to hyperemia and plasma
high-sensitivity C-reactive protein and fibrinogen levels were changed to a greater extent with
combined therapy when compared with atorvastatin or fenofibrate alone (p  0.001, p 
0.182, and p  0.015 by analysis of variance [ANOVA], respectively). The effects of
combined therapy or fenofibrate alone on plasma adiponectin levels and insulin sensitivity
(determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) were signifi-
cantly greater than those of atorvastatin alone (p  0.022 for adiponectin and p  0.049 for
QUICKI by ANOVA). No patients were withdrawn from the study as the result of serious
adverse effects.
CONCLUSIONS Combination therapy is safe and has beneficial additive effects on endothelial function in
patients with combined hyperlipidemia. (J Am Coll Cardiol 2005;45:1649–53) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.052the American College of Cardiology Foundation
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digh serum cholesterol and elevated low-density lipopro-
ein (LDL) cholesterol are important risk factors for coro-
ary heart disease. Many patients on statin therapy have
nitial or recurrent coronary heart disease events despite
eductions in LDL cholesterol (1). Interestingly, fibrate
herapy, which significantly decreases triglycerides and in-
reases high-density lipoprotein (HDL) cholesterol without
educing LDL cholesterol, is associated with significant
ecreases in coronary events (2). Moreover, combined ther-
py with statins and fibrates is more effective in controlling
therogenic dyslipidemia in patients with combined hyper-
ipidemia than the administration of either drug alone (3).
f concern is the fact that the combination of statins and
brates is more likely to be accompanied by severe myop-
thy (4). This limitation is not observed with fenofibrate,
nd no significant side effects have been reported with
ombined statin and fenofibrate treatment (3–5).
Coronary heart disease frequently is associated with
nsulin resistance and metabolic disorders, such as obesity
nd combined hyperlipidemia. Endothelial dysfunction as-
ociated with cardiovascular diseases may contribute to
From the Departments of *Cardiology and †Laboratory Medicine, Gachon
edical School, Incheon, Korea; and the ‡Diabetes Unit, National Center for
omplementary and Alternative Medicine, National Institutes of Health, Bethesda,
aryland. This study was partly supported by grant 2002-5 from the Korean Society
f Circulation.t
Manuscript received November 17, 2004; revised manuscript received January 17,
005, accepted February 8, 2005.nsulin resistance (6). The effects of statins on insulin
esistance are controversial (7,8). Peroxisome proliferator-
ctivated receptor-alpha activators improve insulin sensitiv-
ty in rodents (9). The impact of atovastatin and fenofibrate
herapies on endothelial homeostasis and insulin resistance
ay differ because the mechanisms underlying the biologi-
al actions of these drugs are distinct. Therefore, we
nvestigated whether combined therapy has additive bene-
cial effects greater than atovastatin or fenofibrate alone in
atients with combined hyperlipidemia.
ETHODS
tudy population and design. Fifty-six patients with com-
ined hyperlipidemia (total cholesterol 200 mg/dl and
riglycerides ranging from 200 mg/dl to 800 mg/dl) partic-
pated in this study. We excluded patients with overt liver
isease, chronic renal failure, hypothyroidism, myopathy,
ncontrolled diabetes, severe hypertension, stroke, acute
oronary events, coronary revascularization within the pre-
eding three months, or evidence of alcohol abuse. Clinical
haracteristics of the study patients are summarized in Table
. We administered atorvastatin 10 mg and placebo, ator-
astatin 10 mg and fenofibrate 200 mg, or fenofibrate 200
g and placebo daily during two months in a randomized,
ouble-blind, placebo-controlled crossover trial with three
reatment arms (each two months in duration) and two
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ere observed at 14-day intervals (or more frequently)
uring the study. To avoid side effects, we measured serum
sparate aminotransferase, alanine aminotransferase, creat-
ne kinase, blood urea nitrogen, and creatinine before and
fter therapy. Calcium channel or beta adrenergic blockers
ere withheld for 48 h before the study. The study was
pproved by the Gil Hospital Institute Review Board, and
ll participants gave written, informed consent.
aboratory assays. Blood samples were obtained at 8:00
M after an overnight fast before and after each two-month
reatment period. Samples were immediately coded so that
nvestigators performing laboratory assays were blinded to
ubject identity or study sequence. Assays for lipids, glucose,
nd plasma adiponectin were performed in duplicate by
nzyme-linked immunosorbent assay (R & D Systems, Inc.,
inneapolis, Minnesota), assays for high-sensitivity
-reactive protein levels by latex agglutination (CRP-
atex(II), Denka-Seiken, Japan), and assays for plasma insulin
evels by immunoradiometric assay (INSULIN-RIABEAD II,
bbott Japan, Japan) as described previously (10,11). The
uantitative Insulin-Sensitivity Check Index (QUICKI), a
urrogate index of insulin sensitivity, was calculated as follows:
UICKI  1/[log(insulin)  log(glucose)] (12).
ascular studies. Imaging studies of the right brachial
rtery were performed using an ATL HDI 3000 ultrasound
achine (Bothell, Washington) equipped with a 10-MHz
inear-array transducer, on the basis of a published tech-
ique (10,11).
tatistical analysis. Data are expressed as mean SEM or
edian (range, 25% to 75%). After testing data for normal-
ty, we used the Student paired t or Wilcoxon signed rank
est to compare values before and after each treatment
Tables 2 and 3). The effects of the three therapies were
Abbreviations and Acronyms
ANOVA  analysis of variance
FMD  flow-mediated dilation
HDL  high-density lipoprotein
LDL  low-density lipoprotein
QUICKI  Quantitative Insulin-Sensitivity Check Index
able 1. Baseline Characteristics of the Study Population
Variables n  56
ge 56  1
ender, M:F 23:33
ody mass index, kg/m2 25.5  0.3
isk factors
Current smoking 12 (21)
Ischemic heart disease 12 (21)
Hypertension 38 (68)
Diabetes 9 (16)
edications
Beta-adrenergic blockers 23 (41)
Calcium channel blockers 21 (38)alues are expressed as means  SEM or n (%). Ta
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May 17, 2005:1649–53 Fenofibrate Combined With Atorvastatinnalyzed by one-way repeated measures analysis of variance
ANOVA) or Friedman’s repeated ANOVA on ranks by
omparing the relative changes in values in response to
reatment. Post hoc comparisons between treatment pairs
ere made with the Student-Newman-Keuls multiple com-
arison procedure. Pearson or Spearman correlation coeffi-
ient analysis was used to assess associations between
easured parameters. Comparisons between endothelium-
ependent dilation among the three treatment schemes
ere prospectively designated as the primary study end
oint. All other comparisons were considered secondary. A
alue of p  0.05 was considered to be statistically
ignificant.
ESULTS
o significant differences among baseline values before each
reatment period or carryover effects were noted (Tables 2
nd 3).
ffects on lipids. Fenofibrate alone or combined therapy
ignificantly lowered triglycerides and increased HDL cho-
esterol and apolipoprotein A-I levels when compared with
torvastatin alone (Fig. 1, Table 2).
ffects on vasomotor function. Atorvastatin, combined
herapy, or fenofibrate significantly improved the percent
ow-mediated dilator response to hyperemia relative to
aseline measurements by 46  9%, 81  12%, and 45 
%, respectively (all p  0.001). Of note, combined therapy
ignificantly improved this response more than atorvastatin
r fenofibrate alone (p 0.001 by ANOVA) (Fig. 2, Table 2).
rachial artery dilator response to nitroglycerin was not
ignificantly changed from respective baseline values. After
ombined therapy, improvement in flow-mediated dilation
FMD) correlated with changes in total cholesterol (r 
0.373 and p  0.005), triglycerides (r  0.288 and p 
.032), and apolipoprotein B levels (r  0.341, p 
.010).
ffects on acute-phase reactants. Atorvastatin, combined
herapy, or fenofibrate significantly lowered plasma high-
ensitivity C-reactive protein levels relative to baseline
igure 1. Fenofibrate alone or combined therapy significantly lowered
riglycerides and increased high-density lipoprotein cholesterol levels when
ompared with atorvastatin alone. ANOVA  analysis of variance.measurements from 1.20 to 0.75 (p  0.006), 1.20 to 0.60Ta
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Fenofibrate Combined With Atorvastatin May 17, 2005:1649–53p  0.001), and 0.80 to 0.70 mg/l (p  0.002), respec-
ively. However, the magnitude of reduction among the
hree therapies was similar (p  0.182 by ANOVA).
enofibrate alone or combined therapy significantly lowered
lasma fibrinogen levels relative to baseline measurements
both p  0.001). Of note, combined therapy significantly
educed this more than atorvastatin alone (p  0.015 by
NOVA) (Fig. 3, Table 2).
ffects on adiponectin and insulin resistance. There were
ignificant inverse correlations between baseline adiponectin
nd baseline triglycerides (r  0.277, p  0.039 before
torvastatin; r  0.335, p  0.012 before combined
herapy; and r  0.288, p  0.032 before fenofibrate).
here were significant correlations between baseline adi-
onectin and baseline HDL cholesterol (r  0.284, p 
.034 before atorvastatin; r  0.258, p  0.049 before
ombined therapy; and r  0.353, p  0.008 before
enofibrate). However, there were no significant correlations
etween baseline adiponectin and baseline insulin or
UICKI.
Combined therapy or fenofibrate alone significantly in-
reased plasma adiponectin levels relative to baseline mea-
urements from 3.4 to 3.5 (p  0.001) and 3.2 to 3.6 (p 
.004), respectively. These increases were significantly
igure 2. Percent change in flow-mediated dilation from respective pre-
reatment values after treatment with atorvastatin alone, combined therapy,
nd fenofibrate alone. ANOVA  analysis of variance.
igure 3. Fenofibrate alone or combined therapy significantly lowered
lasma fibrinogen levels relative to baseline measurements. Combined
herapy significantly reduced levels more than atorvastatin alone. ANOVA
analysis of variance.
U
areater than those observed with atorvastatin alone (p 
.022 by ANOVA) (Fig. 4, Table 3). The three therapies
id not have significantly different baseline insulin and
lucose levels. However, the magnitude of reduction of
nsulin with combined therapy was significantly greater than
ith atorvastatin alone (p  0.012 by ANOVA) (Table 3).
ombined therapy or fenofibrate alone significantly in-
reased QUICKI relative to baseline measurements by 7 
% (p  0.003) and 5  2% (p  0.043), respectively.
hese increases with combined therapy were significantly
reater than those observed with atorvastatin alone (p 
.049 by ANOVA) (Fig. 4, Table 3). There were significant
orrelations between percent changes in adiponectin and
ercent changes in QUICKI (r  0.283, p  0.034) or
polipoprotein A-I (r  0.351, p  0.008), and there were
ignificant inverse correlations between percent changes in
diponectin and percent changes in insulin (r  0.332,
 0.013) after combined therapy. However, there were no
ignificant correlations between percent changes in adi-
onectin levels and percent changes in triglycerides (r 
.085) or HDL cholesterol levels (r  0.048).
afety and adverse effects. No patients were withdrawn
rom the study because of serious adverse effects (Table 4).
levations in liver and muscle enzymes and gastrointestinal
pset were mainly transient and resolved spontaneously after
atients finished the study.
igure 4. Percent change in adiponectin levels (left) and in Quantitative
nsulin-Sensitivity Check Index (QUICKI) (right) from respective pre-
reatment values after treatment with atorvastatin alone, combined therapy,
nd fenofibrate alone. ANOVA  analysis of variance.
able 4. Adverse Effects of Atorvastatin, Combined Therapy,
nd Fenofibrate in Patients With Combined Hyperlipidemia
Atorvastatin
(%)
Combined
Therapy (%)
Fenofibrate
(%)
iver enzymes
41–120 IU
4 (7) 8 (14) 4 (7)
iver enzymes
121–136 IU
1 (2) 1 (2) 2 (4)
reatine kinase
201–629 IU
1 (2) 4 (7) 2 (4)
astrointestinal upset 2 (4) 5 (9) 4 (7)pper limits of normal of liver enzymes (serum aminotransferases: alanine and
spartate) and creatine kinase are 40 IU and 200 IU, respectively.
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n patients with combined hyperlipidemia, atorvastatin and
enofibrate therapy alone changed the lipoprotein profiles as
xpected. We reasoned that distinct biological actions of
torvastatin and fenofibrate therapies on lipoproteins, fi-
rinogen, adiponectin, and insulin sensitivity may improve
ndothelium-dependent vascular function by different
echanisms. Indeed, although monotherapy with atorva-
tatin or fenofibrate significantly improved lipid profiles,
ndothelial function, inflammatory markers, and insulin
ensitivity, combined therapy had additional substantial and
ignificant beneficial effects on these parameters over those
een with monotherapy for either drug. The enhanced
ascular reactivity we observed with combination therapy
ay be the result of both changes in lipoprotein profiles as
ell as other effects, including pleiotropic actions of statins
nd actions of fenofibrate to increase nitric oxide production
13). Importantly, no patients were withdrawn from our
tudy as the result of serious adverse effects.
Fenofibrate therapy alone resulted in significant elevation
f adiponectin levels, decreased insulin levels, and increased
nsulin sensitivity (assessed by QUICKI). The present study
s the first report demonstrating that fenofibrate therapy can
ncrease adiponectin levels. Adiponectin is an adipose-
erived factor that augments and mimics metabolic actions
f insulin. Moreover, adiponectin can directly stimulate
itric oxide production from endothelium (14). Therefore,
ncreasing adiponectin levels would be predicted to improve
oth insulin sensitivity and endothelial function by multiple
echanisms. Interestingly, in contrast to effects of combi-
ation therapy on FMD, the beneficial effects of fenofibrate
herapy on adiponectin levels, insulin levels, and insulin
ensitivity did not increase further with combination ther-
py. Thus, the benefits with respect to insulin resistance are
redominantly the result of fibrate therapy rather than statin
herapy, which suggests that improving endothelial function
er se (as reflected by FMD) may not completely explain
ffects of fenofibrate or combined therapy to improve insulin
ensitivity. However, combined therapy may reduce insulin
esistance by multiple mechanisms such as lipoprotein
hanges and peroxisome proliferator-activated receptor-
lpha activators. Fenofibrate or combined therapy for two
onths increased adiponectin levels without a change in
ody weight or body mass index, which raises the possibility
hat drug therapy is directly altering adiponectin levels
ndependent of adiposity. It is possible that monotherapy
ith doses of statins higher than those used in our present
tudy may have additional benefits similar to those we
bserved with our combined fibrate/statin therapy. How-
ver, caution is indicated because recent clinical studies
uggest high doses of statins may increase the onset of new
iabetes (15). In summary, our study suggests that com-
ined atorvastatin/fenofibrate therapy is safe and has bene-
cial additive effects, supporting the updated Nationalholesterol Education Program Adult Treatment Panel III
uidelines (16).
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